Ginkgo Bioworks Holdings, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cell Engineering revenue (1) | $132,746 | $173,972 | $143,531 |
| Biosecurity revenue: | |||
| Service | 37,409 | 53,071 | 78,975 |
| Product | — | — | 28,949 |
| Total revenue | 170,155 | 227,043 | 251,455 |
| Costs and operating expenses: | |||
| Cost of Biosecurity service revenue | 31,521 | 38,549 | 46,524 |
| Cost of Biosecurity product revenue | — | — | 7,481 |
| Cost of other revenue | 15,451 | 5,999 | — |
| Research and development | 243,773 | 424,061 | 580,621 |
| General and administrative | 183,290 | 246,161 | 385,025 |
| Impairment of lease assets | — | — | 96,210 |
| Goodwill impairment | — | 47,858 | — |
| Restructuring charges | 11,398 | 24,172 | — |
| Total operating expenses | 485,433 | 786,800 | 1,115,861 |
| Loss from operations | (315,278) | (559,757) | (864,406) |
| Other income (expense): | |||
| Interest income | 22,616 | 38,612 | 57,217 |
| Interest expense | — | (94) | (93) |
| Loss on equity method investments | — | — | (2,635) |
| Loss on investments | (16,411) | (28,827) | (54,827) |
| Loss on deconsolidation of subsidiaries | — | (7,013) | (42,502) |
| Change in fair value of warrant liabilities | — | 5,701 | 5,168 |
| Other (expense) income, net | (4,527) | 3,870 | 9,138 |
| Total other income (expense) | 1,678 | 12,249 | (28,534) |
| Loss before income taxes | (313,600) | (547,508) | (892,940) |
| Income tax benefit | (837) | (479) | (71) |
| Net loss | $(312,763) | $(547,029) | $(892,869) |
| Net loss per share | $(5.64) | $(10.54) | $(18.37) |
| Weighted average common shares outstanding: | 55,457,676 | 51,894,639 | 48,610,507 |
| Comprehensive loss: | |||
| Net loss | $(312,763) | $(547,029) | $(892,869) |
| Other comprehensive income (loss): | |||
| Foreign currency translation adjustment | 3,531 | (4,782) | 4,116 |
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | — | 1,492 | — |
| Unrealized gain on available-for-sale securities | 126 | — | — |
| Total other comprehensive income (loss) | 3,657 | (3,290) | 4,116 |
| Comprehensive loss | $(309,106) | $(550,319) | $(888,753) |
(1)Includes related party revenue of $8,784, $53,041, and $22,222 for the years ended December 31, 2025, 2024, and 2023, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.